Transitional cell papilloma

Summary

Transitional cell papilloma (MONDO:0005605) is a disease. A subtype of papilloma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	transitional cell papilloma
Mondo ID	MONDO:0005605
EFO	EFO:0006497
DOID	DOID:2670
NCIT	C4115
UMLS	C0334266
MedGen	137734
Is cancer (heuristic)	no

Also known as: papilloma, transitional cell, benign · transitional cell papilloma NOS (morphologic abnormality) · transitional cell papilloma, benign (morphologic abnormality)

Disease family

This is a subtype of papilloma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › papillary epithelial neoplasm › papilloma › transitional cell papilloma

Related subtypes (13): squamous papilloma, intraductal papilloma, serous surface papilloma, fallopian tube papilloma, verrucous papilloma, skin papilloma, inverted papilloma, cervical mullerian papilloma, lung papilloma, choroid plexus papilloma, glandular papilloma, papilloma of buccal mucosa, laryngeal papillomatosis

Subtypes (2): inverted transitional cell papilloma, urothelial papilloma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.